Related Experiment Video

Updated: Jul 5, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells

R Magrini1, D Russo, L Ottaggio

  • 1Molecular Mutagenesis and DNA Repair Unit, Department of Epidemiology and Prevention, National Cancer Research Institute (IST), Genova, Italy.

Journal of Cellular Biochemistry
|April 30, 2008
PubMed

Insights

The novel molecule PRIMA-1 shows potential in treating non-small cell lung cancer (NSCLC). PRIMA-1, combined with adriamycin, effectively induces apoptosis in NSCLC cells, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • p53-dependent apoptosis is crucial for cancer treatment efficacy.
  • Tumors with mutant p53 often display resistance to chemotherapy.
  • Non-small cell lung cancer (NSCLC) cells are frequently resistant to cytotoxic drugs.

Purpose of the Study:

  • To investigate the apoptosis-inducing effects of PRIMA-1 in NSCLC cell lines with varying p53 statuses.
  • To evaluate PRIMA-1's potential to restore p53 transcriptional activity and induce tumor cell death.

Main Methods:

  • Utilized three NSCLC cell lines: A549 (wild-type p53), LX1 (mutant p53 R273H), and SKMes1 (mutant p53 R280K).
  • Assessed the effects of PRIMA-1 alone and in combination with adriamycin on cell viability and apoptosis induction.
  • Monitored key apoptosis markers such as PARP cleavage and DNA fragmentation.

Main Results:

  • PRIMA-1 alone reduced cell viability but did not induce apoptosis.
  • PRIMA-1 potentiated adriamycin-induced apoptosis in A549 and LX1 cell lines.
  • Combined treatment in SKMes1 cells induced PARP cleavage without significant DNA fragmentation, suggesting alternative cell death pathways.

Conclusions:

  • PRIMA-1 may induce cell death via non-apoptotic pathways in NSCLC cells.
  • PRIMA-1 synergizes with adriamycin to promote an apoptotic response in NSCLC.
  • This combination therapy holds promise for overcoming chemoresistance in NSCLC.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...